Explore the Agenda
8:00 am Morning Coffee and Check-In
Workshop A
9:00 am Workshop A: Emerging Clinical & Regulatory Insights to Inform Development Strategy in Autoimmune Clinical Trails
As T-Cell Engager developers look beyond oncology into the complex landscape of autoimmune
disease, the rules of safety, dosing, and trial design change dramatically. This interactive workshop
will equip you with the critical clinical, translational, and regulatory insights needed to navigate these uncharted waters. Learn how to optimise dosing and prophylaxis to minimize CRS and neurotoxicity, manage the unique risks of B cell targeting and T cell activation in dysregulated immune systems, and adapt your molecule design and trial strategy for success across indications. If you’re planning to bring your TCE program into autoimmune disease, this is the must-attend strategy session to future-proof your clinical development pathway.
This workshop will cover:
- Key lessons from clinical T-Cell Engager trials – recurring safety, efficacy, and translational challenges, and how to proactively address data gaps to improve later-stage success
- Optimising dosing and prophylaxis – strategies to mitigate CRS, neurotoxicity, and other immune related toxicities, with comparison of tolerability thresholds between oncology and autoimmune disease settings
- Oncology vs. autoimmune disease differences – impact of B cell targeting and T cell activation dynamics, including risks of stimulating hypoactive or hyper-excitable T cells in autoimmune patients
- Translational and regulatory considerations for FIH studies – integrating preclinical insights, model limitations, and risk mitigation strategies to meet safety and regulatory requirements
- Tailoring molecular and trial design across indications – adapting formats, mechanisms, and study designs for oncology versus autoimmune disease, and best practices for engaging regulators on cross-indication programs
12:00 pm Lunch Break
Workshop B
1:00 pm Supercharging T-Cell Engager Efficacy with Co-Stimulation: Formats, Targets & Strategies to Achieve Durable Responses with Improved Potency & Avidity
As T cell engagers push into solid tumours and earlier-line settings, co-stimulation has emerged as one of the most promising levers for boosting efficacy and durability. This high-impact strategy workshop brings together pioneering T-cell engager experts to tackle which co-stimulatory receptor to target, how to time activation signals, and whether to build into a single trispecific or deliver sequentially. You’ll gain practical, actionable insights on overcoming tumour microenvironment barriers, managing exhaustion, and minimising safety risks. If you’re serious about engineering next-generation TCEs that deliver longlasting responses, this is the must-attend session to get ahead of the curve.
This workshop will cover:
- Clarifying the biological rationale – How co-stimulatory domains (CD28, CD137, CD2 etc.) enhance T cell fitness, prevent early exhaustion, and improve anti-tumour activity and aligning primary CD3 activation with co-stimulation signals to maximise efficacy and avoid mismatched signalling
- Choosing the right co-stimulatory target – Comparative advantages, limitations, and clinical unknowns for different T-cell engager targets
- Design and delivery strategies – How linking co-stimulatory elements directly to the engager can optimise timing, localisation, and therapeutic effect
- Managing exhaustion and safety risks – Avoiding on-target/off-tumour risks by activation of non tumour T cell subsets, reducing CRS, and limiting Fc-mediated toxicity
- Combinations vs trispecifics – Comparing strategies, advantages, and limitations – looking at clinical data